Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018

Tuberculosis patients “resistant to isoniazid and susceptible to rifampicin (Hr-TB)” remain neglected, despite a high burden and poor outcomes. The World Health Organization (WHO) recommends a 6 month regimen consisting of levofloxacin, rifampicin, ethambutol, and pyrazinamide (LRZE) to treat Hr-TB....

Descripción completa

Detalles Bibliográficos
Autores principales: Sayfutdinov, Zayniddin, Kumar, Ajay, Nabirova, Dilyara, Gadoev, Jamshid, Turaev, Laziz, Sultanov, Sanjar, Alaverdyan, Sevak, Parpieva, Nargiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001662/
https://www.ncbi.nlm.nih.gov/pubmed/33799350
http://dx.doi.org/10.3390/ijerph18062965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001662/
https://www.ncbi.nlm.nih.gov/pubmed/33799350
http://dx.doi.org/10.3390/ijerph18062965

Ejemplares similares